Organization
AbbVie Deutschland GmbH & Co. KG
4 abstracts
Abstract
Dose optimization and exposure-response analyses to support optimal dose of ABBV-400, a novel C-met–targeting antibody drug conjugate, in patients with metastatic colorectal cancer (mCRC).Org: AbbVie Deutschland GmbH & Co. KG,
Abstract
Association Between Clinically Meaningful Improvements in Patient-Reported Outcomes and Stringent Measures of Disease Activity in Patients With Psoriatic Arthritis Treated With Upadacitinib Versus Placebo or Adalimumab: Results From a Phase 3 TrialOrg: AbbVie Inc., North Chicago, IL, AbbVie Deutschland GmbH & Co. KG,
Abstract
A COMPARISON OF UPADACITINIB PLUS METHOTREXATE AND UPADACITINIB PLUS OTHER CSDMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS: AN ANALYSIS OF TWO PHASE 3 STUDIESOrg: Albany Medical College, Ghent University Hospital and Ghent University, Kantonsspital St Gallen, Universidade Federal do Paraná, Charité-Universitätsmedizin Berlin,
Abstract
ASSOCIATION BETWEEN ACHIEVEMENT OF LOW DISEASE ACTIVITY OR REMISSION WITH IMPROVEMENT IN QUALITY OF LIFE IN UPADACITINIB-TREATED PATIENTS IN THE PHASE 3 SELECT-PsA 1 AND 2 STUDIESOrg: AbbVie Inc., North Chicago, IL, Rheumatology and Fraunhofer ITMP - Translational Medicine and Pharmacology, AbbVie Deutschland GmbH & Co. KG, Griffith University, Rheumatology Research Unit,